Hence, it appears that ablative radiotherapy triggers a temporal cascade of IFNs, which is well-known from the field of tumor immunoediting, where IFN-α/β produced by CD11c+ cells (presumably DCs and macrophages) enhances the cross-priming activity of CD8α+ DCs, thus stimulating the generation of IFN-γ producing CD8+ T cells, and finally tumor rejection (Figure 5; Diamond et al., 2011; Fuertes et al., 2011). The gene discussed is IFNA1; the disease is neoplasm.